Tarsons Products Limited
NSE: TARSONSINE144Z01023·Healthcare·www.tarsons.com ↗·Mcap ₹1,788 Cr·Listed 2021
₹332.75▼ ₹2.70  (−0.80%)
52W: ₹164 – ₹375 · Vol: 97.1K shares · Close 25 Sept
Set Alert

Quarterly results

consolidated · as filed with NSE · Q1 FY27 back to Q3 FY22
₹ croreQ1 FY27Q4 FY26Q3 FY26Q2 FY26Q1 FY26Q4 FY25Q3 FY25Q2 FY25Q1 FY25Q4 FY24Q3 FY24Q4 FY22Q3 FY22
Revenue from operations11012110810291.411395.799.284.810661.884.970.7
Other income66.68.45.83.33.80.88.42.93.43.22.62.5
Total expenses11812210710391.710188.592.881.492.151.548.344.2
EBITDA2634.331.527.424.73729.625.318.830.222.944.333.1
EBITDA margin23.6%28.3%29.2%26.8%27.0%32.9%31.0%25.5%22.1%28.6%37.0%52.2%46.9%
Finance costs6.36.365.25.15.254.84.34.32.50.51.4
Depreciation2729.12522.519.92017.4141112.310.17.25.3
Profit before tax−1.35.87.55.6315.6814.96.31713.639.228.9
Tax0.11.62.52.31.25.42.84.62.36.73.69.87.4
Net profit−1.44.253.31.810.25.310.3410.39.929.521.5
Net margin-1.3%3.5%4.7%3.2%2.0%9.1%5.5%10.4%4.7%9.8%16.1%34.7%30.4%
EPS (₹)-0.270.790.950.620.341.920.991.930.751.941.875.694.14
Net profit YoY−181.0%−59.0%−4.2%−67.7%−55.6%−1.1%−47.0%––––––

Annual results

financial years ending March · from the fourth-quarter filings
₹ croreFY26FY25FY24FY22
Revenue from operations423392296301
Other income24.21611.58.5
Total expenses424364247174
EBITDA11811199.8153
EBITDA margin27.9%28.2%33.7%50.8%
Finance costs22.519.410.14.2
Depreciation96.562.540.422
Profit before tax21.944.860.8135
Tax7.61518.134.3
Net profit14.329.842.6101
Net margin3.4%7.6%14.4%33.5%
EPS (₹)2.695.608.0119.46
Net profit YoY−51.9%−30.2%––
EPS is as filed for each period and is not restated for later bonus issues or splits.

Cash flow

annual · ₹ crore
₹ croreFY26FY25FY24FY22
Operating cash flow11811410383.5
Investing cash flow−130−145−285−138
Financing cash flow8.938.9136130
Capital expenditure126152184132
Free cash flow (CFO − capex)−7.1−37.5−81.6−48.5

Net profit trend

annual, ₹ crore
FY22
₹101
FY24
₹42.6−58%
FY25
₹29.8−30%
FY26
₹14.3−52%

Result filings

as filed with NSE · PDF and XBRL
PeriodBasisFiledDocuments
Q1 FY27Consolidated10 Aug 2026PDF on NSE XBRL
Q1 FY27Standalone10 Aug 2026PDF on NSE XBRL
Q4 FY26Consolidated · audited–PDF on NSE XBRL
Q4 FY26Consolidated · audited22 May 2026PDF on NSE XBRL
Q4 FY26Standalone · audited22 May 2026PDF on NSE XBRL
Q3 FY26Consolidated6 Feb 2026PDF on NSE XBRL
Q3 FY26Standalone6 Feb 2026PDF on NSE XBRL
Q2 FY26Consolidated12 Nov 2025PDF on NSE XBRL
Q2 FY26Standalone12 Nov 2025PDF on NSE XBRL
Q1 FY26Consolidated12 Aug 2025PDF on NSE XBRL

Annual reports

NSE archive
Key ratios
P/E (TTM)5Y avg 55.0×159.6×
P/B5Y avg 2.76×2.79×
ROEFY26, on average equity2.3%
Net margin3.4%
Debt / equity0.60×
Revenue CAGR (3Y)12.0%
Profit CAGR (3Y)-47.8%
EPS (TTM)₹2.09
Market cap₹1,770 Cr
Computed from the filings and the last close. Market cap uses the latest share count from the balance sheet.
P/B vs history
2.79×
vs 5-point avg 2.76× (+1%)
1.40× low2.76× avg3.84× high
History points are balance-sheet dates (2024 → 2026), priced at the adjusted close on each date.
Balance sheet 31 Mar 2026
Total assets₹1,186 Cr+10%
Net worth₹635 Cr+1%
Total borrowings₹383 Cr+16%
Cash & bank balances₹23 Cr−8%
Investments₹0 Cr
Inventories₹130 Cr+3%
Trade receivables₹85 Cr+7%
Trade payables₹20 Cr+29%
Change vs the same date a year earlier.
Revenue mix FY26
India78.8%result ₹132 Cr
Germany21.2%result ₹9.8 Cr
Segment revenue as reported, before inter-segment eliminations.
Shareholding 30 Jun 2026
%Jun 26Mar 26Dec 25Sept 25Jun 25Mar 25Dec 24Sept 24Jun 24Mar 24Dec 23Sept 23
Promoter47.3047.3047.3047.3147.3147.3147.3147.3147.3147.3147.3147.31
FII0.160.872.475.829.149.527.518.047.958.166.837.85
DII0.100.190.000.080.040.290.500.210.120.182.603.16
Retail22.5821.5420.3317.1415.4215.3015.3713.0613.5313.4412.7711.63
Other public29.8630.1029.9029.6528.0927.5829.3131.3831.0930.9130.4930.05
83,453 shareholders · NSE shareholding pattern filings.